2024-11-012025-10-312025-10-31falseSC310633CLINIC 21 LTD2026-10-31falseiso4217:GBPxbrli:pureSC3106332024-10-31SC3106332025-10-31SC3106332024-11-012025-10-31SC3106332023-10-31SC3106332024-10-31SC3106332023-11-012024-10-31SC310633bus:SmallEntities2024-11-012025-10-31SC310633bus:AuditExempt-NoAccountantsReport2024-11-012025-10-31SC310633bus:FullAccounts2024-11-012025-10-31SC310633bus:PrivateLimitedCompanyLtd2024-11-012025-10-31SC310633core:WithinOneYear2025-10-31SC310633core:AfterOneYear2025-10-31SC310633core:WithinOneYear2024-10-31SC310633core:AfterOneYear2024-10-31SC310633core:ShareCapital2025-10-31SC310633core:SharePremium2025-10-31SC310633core:RevaluationReserve2025-10-31SC310633core:OtherReservesSubtotal2025-10-31SC310633core:RetainedEarningsAccumulatedLosses2025-10-31SC310633core:ShareCapital2024-10-31SC310633core:SharePremium2024-10-31SC310633core:RevaluationReserve2024-10-31SC310633core:OtherReservesSubtotal2024-10-31SC310633core:RetainedEarningsAccumulatedLosses2024-10-31SC310633core:LandBuildings2025-10-31SC310633core:PlantMachinery2025-10-31SC310633core:Vehicles2025-10-31SC310633core:FurnitureFittings2025-10-31SC310633core:OfficeEquipment2025-10-31SC310633core:NetGoodwill2025-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2025-10-31SC310633core:ListedExchangeTraded2025-10-31SC310633core:UnlistedNon-exchangeTraded2025-10-31SC310633core:LandBuildings2024-10-31SC310633core:PlantMachinery2024-10-31SC310633core:Vehicles2024-10-31SC310633core:FurnitureFittings2024-10-31SC310633core:OfficeEquipment2024-10-31SC310633core:NetGoodwill2024-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2024-10-31SC310633core:ListedExchangeTraded2024-10-31SC310633core:UnlistedNon-exchangeTraded2024-10-31SC310633core:LandBuildings2024-11-012025-10-31SC310633core:PlantMachinery2024-11-012025-10-31SC310633core:Vehicles2024-11-012025-10-31SC310633core:FurnitureFittings2024-11-012025-10-31SC310633core:OfficeEquipment2024-11-012025-10-31SC310633core:NetGoodwill2024-11-012025-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-31SC310633core:ListedExchangeTraded2024-11-012025-10-31SC310633core:UnlistedNon-exchangeTraded2024-11-012025-10-31SC310633core:MoreThanFiveYears2024-11-012025-10-31SC310633core:Non-currentFinancialInstruments2025-10-31SC310633core:Non-currentFinancialInstruments2024-10-31SC310633dpl:CostSales2024-11-012025-10-31SC310633dpl:DistributionCosts2024-11-012025-10-31SC310633core:LandBuildings2024-11-012025-10-31SC310633core:PlantMachinery2024-11-012025-10-31SC310633core:Vehicles2024-11-012025-10-31SC310633core:FurnitureFittings2024-11-012025-10-31SC310633core:OfficeEquipment2024-11-012025-10-31SC310633dpl:AdministrativeExpenses2024-11-012025-10-31SC310633core:NetGoodwill2024-11-012025-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2024-11-012025-10-31SC310633dpl:GroupUndertakings2024-11-012025-10-31SC310633dpl:ParticipatingInterests2024-11-012025-10-31SC310633dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-012025-10-31SC310633core:ListedExchangeTraded2024-11-012025-10-31SC310633dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-012025-10-31SC310633core:UnlistedNon-exchangeTraded2024-11-012025-10-31SC310633dpl:CostSales2023-11-012024-10-31SC310633dpl:DistributionCosts2023-11-012024-10-31SC310633core:LandBuildings2023-11-012024-10-31SC310633core:PlantMachinery2023-11-012024-10-31SC310633core:Vehicles2023-11-012024-10-31SC310633core:FurnitureFittings2023-11-012024-10-31SC310633core:OfficeEquipment2023-11-012024-10-31SC310633dpl:AdministrativeExpenses2023-11-012024-10-31SC310633core:NetGoodwill2023-11-012024-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-31SC310633dpl:GroupUndertakings2023-11-012024-10-31SC310633dpl:ParticipatingInterests2023-11-012024-10-31SC310633dpl:GroupUndertakingscore:ListedExchangeTraded2023-11-012024-10-31SC310633core:ListedExchangeTraded2023-11-012024-10-31SC310633dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-11-012024-10-31SC310633core:UnlistedNon-exchangeTraded2023-11-012024-10-31SC310633core:NetGoodwill2025-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2025-10-31SC310633core:LandBuildings2025-10-31SC310633core:PlantMachinery2025-10-31SC310633core:Vehicles2025-10-31SC310633core:FurnitureFittings2025-10-31SC310633core:OfficeEquipment2025-10-31SC310633core:AfterOneYear2025-10-31SC310633core:WithinOneYear2025-10-31SC310633core:ListedExchangeTraded2025-10-31SC310633core:UnlistedNon-exchangeTraded2025-10-31SC310633core:ShareCapital2025-10-31SC310633core:SharePremium2025-10-31SC310633core:RevaluationReserve2025-10-31SC310633core:OtherReservesSubtotal2025-10-31SC310633core:RetainedEarningsAccumulatedLosses2025-10-31SC310633core:NetGoodwill2024-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2024-10-31SC310633core:LandBuildings2024-10-31SC310633core:PlantMachinery2024-10-31SC310633core:Vehicles2024-10-31SC310633core:FurnitureFittings2024-10-31SC310633core:OfficeEquipment2024-10-31SC310633core:AfterOneYear2024-10-31SC310633core:WithinOneYear2024-10-31SC310633core:ListedExchangeTraded2024-10-31SC310633core:UnlistedNon-exchangeTraded2024-10-31SC310633core:ShareCapital2024-10-31SC310633core:SharePremium2024-10-31SC310633core:RevaluationReserve2024-10-31SC310633core:OtherReservesSubtotal2024-10-31SC310633core:RetainedEarningsAccumulatedLosses2024-10-31SC310633core:NetGoodwill2023-10-31SC310633core:IntangibleAssetsOtherThanGoodwill2023-10-31SC310633core:LandBuildings2023-10-31SC310633core:PlantMachinery2023-10-31SC310633core:Vehicles2023-10-31SC310633core:FurnitureFittings2023-10-31SC310633core:OfficeEquipment2023-10-31SC310633core:AfterOneYear2023-10-31SC310633core:WithinOneYear2023-10-31SC310633core:ListedExchangeTraded2023-10-31SC310633core:UnlistedNon-exchangeTraded2023-10-31SC310633core:ShareCapital2023-10-31SC310633core:SharePremium2023-10-31SC310633core:RevaluationReserve2023-10-31SC310633core:OtherReservesSubtotal2023-10-31SC310633core:RetainedEarningsAccumulatedLosses2023-10-31SC310633core:AfterOneYear2024-11-012025-10-31SC310633core:WithinOneYear2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:CostValuation2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-012025-10-31SC310633core:Non-currentFinancialInstrumentscore:CostValuation2025-10-31SC310633core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-10-31SC310633core:Non-currentFinancialInstrumentscore:CostValuation2024-10-31SC310633core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-10-31SC310633core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-10-31SC310633bus:Director12024-11-012025-10-31SC310633bus:Director22024-11-012025-10-31

CLINIC 21 LTD

Registered Number
SC310633
(Scotland)

Unaudited Financial Statements for the Year ended
31 October 2025

CLINIC 21 LTD
Company Information
for the year from 1 November 2024 to 31 October 2025

Directors

Miss E Coulston
Ms K Knox

Company Secretary

Ms K Knox

Registered Address

21 Rutland Place
Glasgow
G51 1TA

Registered Number

SC310633 (Scotland)
CLINIC 21 LTD
Balance Sheet as at
31 October 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Tangible assets340,24953,543
40,24953,543
Current assets
Stocks635595
Cash at bank and on hand4,5112,547
5,1463,142
Creditors amounts falling due within one year4(38,527)(45,096)
Net current assets (liabilities)(33,381)(41,954)
Total assets less current liabilities6,86811,589
Creditors amounts falling due after one year5-(5,129)
Provisions for liabilities(429)(429)
Net assets6,4396,031
Capital and reserves
Called up share capital6,0006,000
Profit and loss account43931
Shareholders' funds6,4396,031
The financial statements were approved and authorised for issue by the Board of Directors on 31 October 2026, and are signed on its behalf by:
Ms K Knox
Director
Registered Company No. SC310633
CLINIC 21 LTD
Notes to the Financial Statements
for the year ended 31 October 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered office is 21 Rutland Place, Glasgow, Scotland, G51 1TA.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS102 have been applied other than where additional disclosure is required to show a true and fair view.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operation for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts. Invoiced services for hair and tattoo removal are recognised when the service is delivered to the customer. Rental income is recognised as the amounts fall due.
Current taxation
Current tax is recognised in profit or loss and represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference. Current and deferred tax assets and liabilities are not discounted.
Tangible fixed assets and depreciation
Tangible assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and impairment losses. Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases: Leasehold improvements - 33% on reducing balance Fixtures and fittings - 10% to 25% on cost Computers - 20% on cost The gain or loss arising on the disposal of an asset is determined as the difference between the sales proceeds and the carrying value of the asset, and is credited or charged to the profit and loss account.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately within current liabilities.
Financial instruments
The company only enters into basic financial instruments that result in the recognition of financial assets like trade debtors and creditors. These are measured at amortised cost and are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of comprehensive income.
2.Average number of employees

20252024
Average number of employees during the year22
3.Tangible fixed assets

Land & buildings

Plant & machinery

Office Equipment

Total

££££
Cost or valuation
At 01 November 2412,792155,957988169,737
Additions--828828
Disposals--(100)(100)
At 31 October 2512,792155,9571,716170,465
Depreciation and impairment
At 01 November 2412,792102,414988116,194
Charge for year-13,98513714,122
On disposals--(100)(100)
At 31 October 2512,792116,3991,025130,216
Net book value
At 31 October 25-39,55869140,249
At 31 October 24-53,543-53,543
4.Creditors: amounts due within one year

2025

2024

££
Bank borrowings and overdrafts2,0003,000
Taxation and social security5,4973,657
Other creditors24,37034,119
Accrued liabilities and deferred income6,6604,320
Total38,52745,096
5.Creditors: amounts due after one year

2025

2024

££
Bank borrowings and overdrafts-2,000
Other creditors-3,129
Total-5,129